Rossari Biotech Ltd (IN:ROSSARI)
:ROSSARI
Top Page
Rossari Biotech Ltd
(ROSSARI)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹405.00
▼(-30.64% Downside)
Action:DowngradedDate:03/14/26
The score is driven primarily by solid fundamentals (growth, improving profitability, and low leverage), partially offset by negative free cash flow. Technicals are notably weak with the stock below key moving averages and bearish momentum indicators, while valuation is mixed with a mid-to-high P/E and minimal dividend support.
Positive Factors
Revenue & margin improvement
Rossari's 13.65% revenue growth alongside a gross margin of 31.10% and EBIT margin of 24.74% indicates durable demand for higher-value speciality formulations and improved operating efficiency. Sustained top-line growth with margin expansion supports pricing power, reinvestment capacity, and more predictable profit generation over the medium term.
Negative Factors
Negative free cash flow
Persistent negative free cash flow, driven by high capital expenditures relative to operating cash flow, constrains liquidity and strategic optionality. Over a multi-month horizon this increases reliance on external financing, limits capacity for dividends or buybacks, and could pressure funding for new projects if capex does not yield proportionate cash returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & margin improvement
Rossari's 13.65% revenue growth alongside a gross margin of 31.10% and EBIT margin of 24.74% indicates durable demand for higher-value speciality formulations and improved operating efficiency. Sustained top-line growth with margin expansion supports pricing power, reinvestment capacity, and more predictable profit generation over the medium term.
Read all positive factors
Rossari Biotech Ltd (ROSSARI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹22.34B
Dividend Yield0.09%
Average Volume (3M)2.66K
Price to Earnings (P/E)24.6
Beta (1Y)0.89
Revenue Growth15.47%
EPS Growth-1.72%
CountryIN
Employees450
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)5.90
Shares Outstanding55,383,366
10 Day Avg. Volume1,386
30 Day Avg. Volume2,661
Financial Highlights & Ratios
PEG Ratio5.98
Price to Book (P/B)2.88
Price to Sales (P/S)1.64
P/FCF Ratio-161.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.3
Revenue Forecast (FY)₹26.13B
Rossari Biotech Ltd Business Overview & Revenue Model
Company Description
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The...
How the Company Makes Money
Rossari Biotech makes money primarily by selling speciality chemical products and formulations to business customers (B2B) across several end markets. Its revenue model is driven by (1) product sales in its key segments—textile speciality chemical...
Rossari Biotech Ltd Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
75
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.22B | 20.80B | 18.31B | 16.56B | 14.83B | 7.07B |
| Gross Profit | 6.42B | 6.47B | 5.26B | 2.80B | 2.29B | 2.29B |
| EBITDA | 2.77B | 2.65B | 2.57B | 2.12B | 1.94B | 1.31B |
| Net Income | 1.37B | 1.36B | 1.31B | 1.07B | 976.74M | 802.20M |
Balance Sheet | ||||||
| Total Assets | 20.88B | 18.96B | 15.72B | 13.68B | 12.57B | 5.61B |
| Cash, Cash Equivalents and Short-Term Investments | 719.76M | 1.14B | 667.85M | 1.52B | 644.26M | 883.57M |
| Total Debt | 3.53B | 2.18B | 1.19B | 739.28M | 84.27M | 0.00 |
| Total Liabilities | 8.36B | 7.11B | 5.24B | 4.52B | 4.52B | 1.53B |
| Stockholders Equity | 12.51B | 11.85B | 10.48B | 9.15B | 8.05B | 4.09B |
Cash Flow | ||||||
| Free Cash Flow | -1.67B | -210.69M | -880.28M | 1.20B | -88.67M | -103.17M |
| Operating Cash Flow | -250.32M | 1.37B | 432.55M | 1.52B | 293.58M | 477.67M |
| Investing Cash Flow | -1.06B | -1.84B | -1.03B | -1.81B | -2.99B | -371.79M |
| Financing Cash Flow | 1.22B | 649.01M | 161.85M | 608.55M | 2.92B | -245.92M |
Rossari Biotech Ltd Technical Analysis
Negative
583.95
Price Trends
488.92
Negative
541.42
Negative
601.87
Negative
Market Momentum
-29.41
Positive
36.41
Neutral
27.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ROSSARI, the sentiment is Negative. The current price of 583.95 is above the 20-day moving average (MA) of 433.87, above the 50-day MA of 488.92, and below the 200-day MA of 601.87, indicating a bearish trend. The MACD of -29.41 indicates Positive momentum. The RSI at 36.41 is Neutral, neither overbought nor oversold. The STOCH value of 27.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ROSSARI.
Rossari Biotech Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹24.20B | 23.71 | ― | 0.65% | -10.12% | -22.38% | |
64 Neutral | ₹22.34B | 24.59 | ― | 0.09% | 15.47% | -1.72% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹21.69B | 23.16 | ― | 0.02% | 6.39% | -15.53% | |
57 Neutral | ₹21.89B | 0.22 | ― | ― | -22.04% | -58.81% | |
39 Underperform | ₹20.30B | 172.94 | ― | ― | -27.80% | -365.69% |
* Basic Materials Sector Average
IN:ROSSARI
Rossari Biotech Ltd
403.40
-223.08
-35.61%
IN:BHARATRAS
Bharat Rasayan Limited
1,304.95
-1,391.96
-51.61%
IN:FCL
Fineotex Chemical Limited
20.87
-3.39
-13.97%
IN:KIRIINDUS
Kiri Industries Limited
364.75
-260.20
-41.64%
IN:ORISSAMINE
Orissa Minerals Development Company Limited
3,383.40
-1,791.75
-34.62%
IN:RPEL
Raghav Productivity Enhancers Ltd.
629.30
87.20
16.09%
Rossari Biotech Ltd Corporate Events
Rossari Biotech Renames Dubai Subsidiary to Comply With DMCC Norms
Mar 24, 2026
Rossari Biotech has announced that its wholly owned subsidiary Rossari Global DMCC has changed its name to Rossari Global FZCO, effective March 23, 2026, following a certificate issued by the Dubai Multi Commodities Centre Authority. The change is...
Rossari Biotech Publishes Extract of Q3 FY26 Consolidated Unaudited Results in Newspapers
Jan 18, 2026
Rossari Biotech Ltd has notified the stock exchanges that it has published in Financial Express and Loksatta an extract of its consolidated unaudited financial results for the quarter and nine months ended 31 December 2025, in compliance with disc...
Rossari Biotech Releases Q3 and 9-Month FY26 Earnings Presentation
Jan 18, 2026
Rossari Biotech Limited has released its earnings presentation for the third quarter and nine months ended December 31, 2025, providing an update to shareholders and the market on its financial performance in the current fiscal year. The disclosur...
Rossari Biotech Delivers Double-Digit Revenue Growth in Q3 FY26 Amid Margin Pressure
Jan 18, 2026
Rossari Biotech reported a solid set of numbers for the quarter ended 31 December 2025, with consolidated revenue from operations rising 13% year-on-year to Rs 581.7 crore, driven by broader demand across its specialty chemicals portfolio. Quarter...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.